Eli Lil­ly, No­var­tis back a $26M round for Cavion’s work on neu­ro­log­i­cal dis­eases

The cor­po­rate ven­ture arms of Eli Lil­ly and No­var­tis are back­ing a $26.1 mil­lion round for Char­lottesville, VA-based Cavion, a start­up fo­cused on a pos­si­ble key me­di­a­tor for neu­ro­log­i­cal dis­eases as well as can­cer.

Their drugs tar­get Cav3, which Cavion’s re­searchers say me­di­ates thal­a­m­o­cor­ti­cal dys­rhyth­mia, cov­er­ing a range of dis­eases such as es­sen­tial tremor, Parkin­son’s dis­ease, neu­ro­path­ic pain, epilep­sy as well as or­phan neu­ro-de­vel­op­men­tal and ge­net­ic dis­or­ders such as An­gel­man Syn­drome and Dravet Syn­drome.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters